A 15 MONTHS, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL COMPARING 18 WEEKS OF TWO DOSES OF OMALIZUMAB TO PLACEBO TO ACCELERATE A SYMPTOM-DRIVEN ORAL IMMUNOTHERAPY SCHEDULE IN SUBJECTS AGED 6 TO 25 YEARS WITH MULTIPLE FOOD ALLERGIES (BOOM)

Registry ID

ITO-OMA-2018-01

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE

Start date

2020-12-16

Last update

2018-12-24

Conditions

• FOOD ALLERGIES

Related clinical trials

• A THREE-YEAR, MULTI-CENTER, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LIGELIZUMAB IN PATIENTS WHO COMPLETED LIGELIZUMAB'S PHASE III STUDIES IN FOOD ALLERGY

View on source registry